Kory James Wentworth - Nov 16, 2022 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role
Chief Financial Officer
Signature
/s/ Jared Cohen, as Attorney-in-Fact
Stock symbol
TRDA
Transactions as of
Nov 16, 2022
Transactions value $
-$3,200
Form type
4
Date filed
11/18/2022, 03:59 PM
Previous filing
Sep 6, 2022
Next filing
Dec 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRDA Common Stock Options Exercise $420 +200 +1.21% $2.10* 16.7K Nov 16, 2022 Direct F1, F2
transaction TRDA Common Stock Sale -$3.62K -200 -1.2% $18.10 16.5K Nov 16, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TRDA Stock Option (Right to Buy) Options Exercise $0 -200 -0.18% $0.00 109K Nov 16, 2022 Common Stock 200 $2.10 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 13, 2022.
F2 The Form 4 filed by the reporting person on August 18, 2022 inadvertently understated the number of common shares owned following the transactions reported therein by 20 shares, an error that was carried forward onto the reporting person's subsequent Form 4 filings. Immediately prior to the transactions reported herein, the correct number of shares of common stock owned by the reporting person was 16,509 shares.
F3 25% of the shares subject to this option shall vest and become exercisable on November 16, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter.